Industrial Biotechnology Innovation and Synthetic Biology Accelerator

IBISBA is a R&D infrastructure project that will:

Support Industrial Biotechnology by facilitating end to end bioprocess design

Accelerate and reduce the cost of R&D in industrial biotechnology

Induce smarter investment in large equipment, and better use and sharing of knowledge


IBISBA explanation

 IBISBA is a research infrastructure project that is currently under evaluation by the esfri committee.

Presently, the IBISBA consortium anticipates that the full-scale build up of IBISBA will begin in 2016 / 2017.

Why now?

Specialists agree that industrial biotechnology will be a cornerstone of the bio-economy, with synthetic biology providing impetus and considerable innovation.

Industrial biotechnology has not yet reached full potential and R&D is costly and time-consuming.

The European chemical industry is facing strong international competition.

European investment in R&D infrastructures is sub-optimally valorised due to technology fragmentation

Advances in information and communication technologies, including process management, now provide new means for collaboration between remote sites.

Europe is well-endowed with a large array of R&D infrastructure for industrial biotechnology. When this is connected, for example in EU-funded projects, the results can be awesome. However, interconnecting infrastructures is a long term challenge that is incompatible with short-term project timeframes. I believe that IBISBA is the only way to create a permanent offer of end-to-end bioprocess development services R&D players.
Michael O’Donohue, Research Director with INRA and IBISBA coordinator. He is a biotechnologist working with INRA and is based in France’s largest industrial biotechnology research laboratory in Toulouse, France (LISBP). Michael has extensive experience of European collaborative actions and has firsthand experience of creating links between European R&D infrastructures.

IBISBA services

IBISBA aims to be central broker for end to end R&D projects in industrial biotechnology. To achieve this, IBISBA will draw together existing facilities and expertise from across Europe within an infrastructure that will cover entire bioprocess development needs, from enzyme and strain construction, to early bioprocess design with downstream processing through to piloting and delivery of demonstration-ready processes.

In its capacity as a unique R&D portal for industrial biotechnology, IBISBA will offer:

Access to repositories of best methods and workflows


IBISBA, the one stop shop

A single contact point for project planning and coordination, and localization of facilities. The use of pre-established contract models and uniform policies will offer clients a transparent, efficient interface for their R&D needs. Moreover, for users seeking access to individual facilities, IBISBA will a consultable database of describing partner expertise and infrastructure.

The expertise included in the IBISBA consortium will be carefully selected to extensively cover the design-build-test-learn and implementation phases of synthetic biology and industrial biotechnology. In the area of synthetic biology, expertise will include chemo- and bioinformatics, numerous HTS platforms for biopart discovery and engineering, and automated pipelines for fast-tracking of strain construction and testing cycle. For bioprocess development, IBISBA will include cell and process modelling systems, comprehensive bioreactor capability and an array of downstream separation and purification technologies.


IBISBA training



Bringing science to society

Recognizing the importance of public buy-in and the need for responsible science, IBISBA's technical offer will be completed by its Ethics, Social and Legal issues platform. This will ensure that every project is subject to a careful benefits-risk appraisal and that public expectations form at the very outset an important design criterion.


Access to repositories of best methods and workflows.

The exchange of methods and the development of workflows will provide the client with access to wealth of standardized experimental resources and a register of best practices that can be re-used for new projects.






IIBISBA the_one_stop_shop




A better way to train

An environment of excellence and advanced technology for in-depth training of tomorrow’s industrial biotechnology R&D workforce. IBISBA will form the focal point of advanced training for early career stage researchers and provide vocational training for professionals.




Screening lipase 


Francisco GIRIO“As Principal Responsible of BBRI which is the only RI dedicated to Biomass and Bioenergy included into the Portuguese Roadmap of RI´s 2014-2020 we are willing to cooperate and to request grant access rights to this future European RI, since the lab-on-chip biochemistry platforms, including the high-throughput equipment’s both for gene cloning and for early stage bioreactor development will complement our national RI on biomass and bioenergy.”

Francisco GIRIO, Head of Bioenergy (LNEG – Laboratório Nacional de Energia e Geologia), Lisboa (Portugal)

Francisco GIRIO

V_Mercati“ R&D forms an integral part of Aboca, a company specialized the production of pharmaceutical and nutraceutical ingredients and products. For this reason, we believe that Aboca could benefit from IBISBA, especially for the manufacture of natural substances. ”

Valentino Mercati, President, Aboca S.p.A Sansepolcro, Italy

Valentino Mercati

“At BioPox srl we are developing novel solutions for manufacturing in a variety of sectors, including chemicals and cosmetics. Our business is centred on enzymes and microbial strains and our aim is assist customers in their transition towards biobased processes. We value partnership with public research infrastructures and thus fully endorse initiatives such as IBISBA, which will offer businesses like ours with a more complete R&D offer.”

Dr. Vincenzo Lettera, Chief Executive Officer BioPox SRL (Italy)

Vincenzo Lettera

jose_teixeira“IBISBA will be important in the implementation of Industrial Biotechnology because it will allow for an Integrative approach to bioprocess development. Overall, IBISBA, I believe that IBISBA can contribute decisively to the creation of a solid basis for the bioeconomy transition in Europe.
Naturally, because Industrial Biotechnology has always been a key research area here in the Centre of Biological Engineering, CEB is fully supporting the creation of IBISBA.”

José António Teixeira – Professor, Director of Research (CEB – Centro de Engenharia Biológica) – Universidade do Minho, Braga, Portugal

José António Teixeira

V_tumiattiSea Marconi Technologies SAS is active in the quest for sustainable solutions for energy and the environment. One of our development sectors is bioenergy and bioproducts. Therefore we recognize IBISBA as an important initiative for the bioeconomy and for European industrial competitiveness.

Vander Tumiatti, General Partner, Sea Marconi Technologies di Vander Tumiatti SAS (Collegno, Italy)

Vander Tumiatti

P_BranduardiIn Galatea Biotech Srl, we know that the development of new biotech products and processes is complex and that highly skilled research personnel are vital for success. Moreover, while many R&D laboratories are able to create biocatalysts for new product manufacture, most are unable to implement the technology in a process. For these reasons, we believe that IBISBA will be a useful support to biotech companies.

Paola Branduardi, President of Galatea Biotech Srl (Milano, Italy)

Paola Branduardi

Pierre_monsan“Bioeconomy is a key challenge for Europe to create jobs for the future. From this point of new, mastering Systems and Synthetic Biology is of prime importance. An efficient European network of technology transfer structures will greatly facilitate the translation of academic research results into products and processes for European companies, based on the use of renewable local raw materials.”

Pierre MONSAN, Founding Director, Toulouse White Biotechnology Ramonville (Saint-Agne, France)


V_de_Lorenzo“ Unlike traditional Genetic Engineering, Synthetic Biology tends to focus on the application of the engineering cycle of design, modelling, construction and testing with a emphasis on  manufacturing concepts including standardization and abstraction. This paradigm shift is bound to radicallychange the way industrial Biotechnology operates, with projections far beyond the traditional realm of this burgeoning economic sector. IBISBA will bring together researchers and industry with their distinct but complementary backgrounds and approaches, which are required to create novel techniques, products and services that will shape the future of Biotechnology. ”

Victor de Lorenzo, Professor and Program Leader, Systems  and Synthetic Biology Program, Centro Nacional de Biotecnologia (Madrid, Spain)

Victor de Lorenzo

Fabrizio Conicella“Bioindustry Park Silvano Fumero is a service provider operating In the field of life sciences. Our activities cover technology transfer, support for company growth, preclinical studies and R&D. Moreover, we manage bioPmed, the Piemonte cluster innovation. From our varied standpoint, we see that companies are increasingly formulating demands for complex, multi-technology services and are particularly interested in industrial biotechnology. Therefore, we strongly believe that multi-facility infrastructure offering easier access to R&D will create a positive environment in Europe for companies and especially start-ups and SMEs.”

Fabrizio Conicella, General manager BioPark Silvano Fumero – SpA (Italy)

Fabrizio Conicella

James Philip“Not only is the European chemical industry under intense pressure to stay competitive, but industrial biotechnology is also being taken up its competitors. Countries such as China have a natural political advantage when it comes to building research capacity. The research fragmentation in Europe needs to be addressed; engineering standards need to be applied across the boards to maximize efficiency in bioprocesses. Taking ten years for bio-based chemicals to reach the market won’t do. Europe will lose.”

James Philip, Policy advisor on biotechnology with the OECD

James Philip

F. Godia“Industrial Biotechnology is a key vector for paradigm change in European industry. This is because Industrial Biotechnology will make industry more efficient, sustainable and environmentally friendly. Inthis respect, IBISBA represents a key step in the right direction, building a very strong and multidiscplinary platform serving the advancement of technology and making industry more research intensive and competitive.”

Francesc Godia, Full Professor of Chemical Engineering, Universitat Autònoma de Barcelona (Catalonia, Spain)

Francesc Godia

G_grogori“ Novamont S.p.A; is interested in IBISBA because we think that IBISBA will help to create new frameworks and value chains between sectors and help to tackle the issue of fragmentation faced by the EU in comparison to its international competitors. ”

Giulia Gregori, Strategic Planning and Corporate Communication Manager, Novamont S.p.A

Giulia Gregori

MJ_Martinez“ The Centro de Investigaciones Biologicas (CSIC) is one of the major Spanish R&D centres dedicated to Biological Research, including a clear focus on industrial Biotechnology. One of the major limitations in biological research today is related to access to cutting edge infrastructures. Cost- and technology sharing through a network of technological infrastructures will definitely boost the research potential of our centre, and of the other participating partners of the IBISBA consortium. ”

Maria Jesus Martinez, Director Centro de Investigaciones Biologicas (CIB – CSIC)

Maria Jesus Martinez

A_Bresin“Building/designing new strains using cutting edge technologies is one thing, but making it work at industrial scale is neither automatic nor obvious. We in ARD have sound experience in the scaling up from lab to demo (180m3) attested by some significant industrial developments. ”

Anthony Bresin, CSO, ARD (Pomacle – France)

Anthony Bresin

“For the academic community of Synthetic Biologists, Industrial Biotechnology is not only viewed as a means to derive potential outcomes from academic discoveries, but also as a powerful driver for scientific innovation in research. IBISBA represents the perfect infrastructure to launch and test novel and ground-breaking scientific ideas. Furthermore, linking educational and ethics platforms to industrial biotechnology projects is essential to maintain a European reservoir of industrial excellence capable of competing in strong international competition.”

Gilles Truan, Director of the French National Academic Group on Synthetic and Systemic Biology, LISBP (Toulouse, France)

Gilles Truan

thierry scholastique“CIMV is pioneering the development of bioprocesses for the production of biofuels and added-value chemicals from renewable lignocellulosic biomass. Presently, we are maturing our technology to demonstration phase and are increasingly faced with the challenge of implementing biotechnological processes. As a SME emerging in the industrial sector, we consider that European initiatives such as IBISBA will be of considerable strategic importance for our future development.”

Thierry Scholastique, Executive Director of CIMV S.A.

Thierry Scholastique

Stanislaw Bielecki“As a Polish leader in the field of industrial biotechnology, TUL is committed to the promotion of this field in the wider European context. Therefore, building on its solid experience of European collaboration and its strong infrastructure capacity, including the BioNanoPark (TUL is a major scientific shareholder), TUL is eager to contribute to IBISBA.”

Prof. Stanislaw Bielecki, Rector of Lodz University of Technology and Director of the Institute of Technical Biochemistry of TUL

Stanislaw Bielecki

J_Quintana“ The aim of our Parc Cientific is to bring together public and private research environments, facilitating the transfer of knowledge and innovation between university and research environments, and the business world. We believe that IBISBA is consistent with this goal and thus we are fully committed to support this infrastructure initiative and the Spanish partners therein. ”

Jordi Quintana, Ph.D., Head, Drug Discovery Platform, Barcelona Science Park (Spain)

Jordi Quintana

JL_Faulon“SYNBIOCHEM is a BBSRC/EPSRC Synthetic Biology research centre hosted by the Manchester Institute of Biotechnology (MIB) at the University of Manchester. Both MIB and SYNBIOCHEM research strategies are clearly closely aligned to that of IBISBA. IBISBA provides a unique opportunity to foster a pan-European multidisciplinary team of leaders, supported by world-class facilities, with the goal of reducing the cultural gap between science and engineering and accelerating the R&D phase of bioprocesses.”

Jean-Loup Faulon, Professor of Synthetic Biology and Systems Metabolic Engineering, SYNBIOCHEM centre Manchester Institute of Biotechnology, School of Chemistry, The University of Manchester


Jean-Loup Faulon

Jari Vehmaanpara“IBC Finland fully endorses IBISBA to support European research infrastructure dedicated to biotechnology and synthetic biology. This undertaking holds great potential for the promotion of European research, education and industry in the fields of biotechnology and the bioeconomy and thus to boost economic growth in the whole area. IBC Finland is definitely among the candidates interested to join IBISBA.”

Jari Vehmaanparä, Chairman of IBC Finland ry The Industrial Biotechnology cluster (IBC)

Jari Vehmaanparä

Akokossis“ NTUA researches state-of-the-art process engineering technologies with a strong emphasis on biorefineries and biorenewables. Our technology focus is on modelling of conventional & novel process equipment, costing and development of integrated industrial flowsheets. This technology is vital to build efficiency (in raw materials, energy, water, sustainability metrics) into industrial plants; it is also important to rapidly introduce promising new chemistries into the industrial environment. IBISBA offers a unique access to biological paths, bio-chemistries and pilot facilities, setting up the ideal background to apply systems technology in real-life problems and numerous opportunities to validate technology and assist the development of commercial plants. ”

Antonis Kokossis, CEng, FIChemE, FRSA, FIET, National Technical University of Athens, School of Chemical Engineering (Athens, Greece)

Antonis Kokossis

V_Maglia“ SPRING, the National Technological Cluster for Green Chemistry, aims to trigger investment in Italy in the biobased sector. For this, we are promoting a holistic approach to innovation that accounts for economic environmental and social sustainability and is aimed at revitalizing the Italian chemical industry. For this reason SPRING supports IBISBA since we expect that it will have positive impact the development of bioprocesses and the bioindustry in Italy. ”

Vittorio Maglia, SPRING, the Italian Cluster of Green Chemistry (Milano, Italy)

Vittorio Maglia

C_Lurigados“ BIOCAT is the organization that coordinates and promotes the biotechnology and biomedicine sector in Catalonia. We recognize the vital contribution that industrial biotechnology will make to the bioeconomy, for this reason BIOCAT is coordinating the Health Community in the framework of RIS3 program, and promoting the Industrial Biotechnology Platform in Catalonia. Also local authorities have chosen to invest in this area, creating infrastructures capacity. IBISBA constitutes a real opportunity for us to streamline our investments and ensure that Catalonia is well linked to the infrastructure network in Europe.”

Carlos Lurigados Delgado, Head of Entrepreneurship and Business Growth, Biocat

Carlos Lurigados Delgado

Anne-Christine_Ritschkoff“VTT strongly supports the IBISBA joint infrastructure in industrial biotechnology. Industrial biotechnology, aligned with the national spearhead on bioeconomy, is one of the key research areas at VTT.
Industrial biotechnology is one of the Key Enabling Technologies (KETs) which facilitates European reindustrialization, economic growth and people´s wellbeing. Joint research infrastructures and pilot facilities like IBISBA speed up development cycle from lab to market and accelerates the crossing of the “valley of death”. IBISBA joint research and pilot infrastructure has significant importance for VTT, Finland and Europe.”

Anne-Christine Ritschkoff, PhD, Prof., Executive Vice President & CTO,  VTT Technical Research Centre of Finland Ltd.

Anne-Christine Ritschkoff

  Key dates

IBISBA is a R&D infrastructure project. In 2016, Europe will update its strategic roadmap for R&D infrastructures. Therefore, in 2015 the ESFRI committee has the task of selecting new infrastructures that will be allowed to enter preparation phase starting in 2016/2017.


  • 16th January 2015 – Information day
    This meeting will take place from 10:00 am at the Centre of AgroParisTech, 16 rue Claude Bernard, Paris, France
    Meeting update: this meeting brought together over 30 participants from 10 EU member states. Discussions during the meeting focused on the presentation of the IBISBA vision and a review of upcoming deadlines, especially the ESFRI submission deadline (31st March 2015).

  • 25th June 2015 – IBISBA workshop
    This workshop will take place from 12:00 pm in the meeting room of the offices of EU Regions Hessen, Emilia-Romagna, Aquitaine and Wielkopolska, 21 rue Montoyer - 1000 Brussels.
    Meeting update: this meeting gathered together over 40 participants, including IBISBA consortium members and external stakeholders. Jim Philp (OECD) and Claire Gray (Europabio) were among the guest speakers.

  • 4th September 2015 – IBISBA consortium meeting
    This internal meeting for IBISBA members will take place as a webinar starting at 10:00 am (CET). Invited participants will receive required connection details via private mail.

  • Mid-September 2015 - Audition of an IBISBA delegation.
    As part of the evaluation process, the IBISBA project will be examined by an expert group of the ESFRI committee. To this end, a 3-person delegation including the project coordinator, Michael O’Donohue, will be auditioned in Brussels. The final decision concerning IBISBA is expected towards the end of 2015.